A growing body of research is offering Puerto Rico’s sizable asthma-affected population a compelling reason to follow developments around semaglutide, the active ingredient in Ozempic and Wegovy. New findings reported by Science Daily and Gizmodo indicate that the widely used weight-loss and diabetes medication is associated with nearly 40 percent fewer asthma attacks among patients who take it — a result that respiratory health specialists are calling significant.
The research, highlighted across multiple outlets including Deseret News and respiratory-therapy.com, found that semaglutide was also tied to fewer exacerbations of chronic obstructive pulmonary disease (COPD). Puerto Rico has historically reported elevated rates of asthma, particularly in urban communities across San Juan, Bayamón, Caguas, and Ponce, where environmental and socioeconomic factors have long compounded respiratory health challenges. For residents in these municipalities managing both obesity and asthma, the dual benefit of semaglutide could represent a meaningful clinical advance.
Physicians and public health officials across the island are likely to weigh these findings carefully, particularly as access to GLP-1 receptor agonist medications has expanded through local health plans and federally qualified health centers serving communities from Mayagüez to Humacao. The medication’s growing profile beyond weight management underscores a broader shift in how clinicians understand metabolic health’s relationship to respiratory function.
As further peer-reviewed studies are published, healthcare providers in Puerto Rico’s public and private sectors — including those serving patients in Arecibo, Guaynabo, and Carolina — will have increasing data to guide prescribing decisions. Patients are encouraged to consult their physicians before making any changes to their treatment plans.
This article was AI-generated from public sources by this publication. We are committed to transparent AI journalism and editorial integrity. Photography is generally stock photography used with permission, unless otherwise indicated. Please verify details with original sources and outlets.
